An Extension Study of APD334-003 in Patients with Moderately to Severely Active Ulcerative Colitis
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2017
At a glance
- Drugs Etrasimod (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Arena Pharmaceuticals
- 06 Sep 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Aug 2018.
- 11 Mar 2017 This trial has been completed in the Czech Republic.
- 09 Dec 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.